Catarina Silva, MSc,  —

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Articles by Catarina Silva

EMA Reviewing Belantamab Mafodotin for Heavily Pretreated Multiple Myeloma

The European Medicines Agency has agreed to review the application of  GlaxoSmithKline‘s belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced in a press release. Specifically, the marketing authorization application is for people with relapsed or refractory disease who received prior treatment with an …